Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
73.05
+2.13 (3.00%)
Mar 6, 2026, 4:00 PM EST - Market closed
Apogee Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 70.88 | 49.01 | 24.58 | 3.21 |
| Research & Development | 214.71 | 167.87 | 68.42 | 30.31 |
| Operating Expenses | 285.6 | 216.87 | 93 | 33.52 |
| Operating Income | -285.6 | -216.87 | -93 | -33.52 |
| Interest & Investment Income | 30.03 | 34.74 | 9.02 | 0.1 |
| Other Non Operating Income (Expenses) | - | - | - | -9.98 |
| Pretax Income | -255.57 | -182.13 | -83.99 | -43.4 |
| Income Tax Expense | 0.28 | 0.02 | - | - |
| Net Income | -255.84 | -182.15 | -83.99 | -43.4 |
| Net Income to Common | -255.84 | -182.15 | -83.99 | -43.4 |
| Shares Outstanding (Basic) | 61 | 55 | 25 | 2 |
| Shares Outstanding (Diluted) | 61 | 55 | 25 | 2 |
| Shares Change (YoY) | 9.96% | 120.72% | 915.57% | - |
| EPS (Basic) | -4.22 | -3.30 | -3.36 | -17.63 |
| EPS (Diluted) | -4.22 | -3.30 | -3.36 | -17.63 |
| Free Cash Flow | -232.6 | -172.33 | -74.93 | -17.92 |
| Free Cash Flow Per Share | -3.83 | -3.12 | -3.00 | -7.28 |
| EBITDA | -284.18 | -216.68 | - | - |
| D&A For EBITDA | 1.42 | 0.19 | - | - |
| EBIT | -285.6 | -216.87 | -93 | -33.52 |
Source: S&P Capital IQ. Standard template.
Financial Sources.